Plant · Scientific monograph
Boswellia serrata
Indian frankincense / Shallaki / Salai guggul
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Inflammatory Pathways, Pain Signaling Research, Neurological & Cognitive Research, Respiratory Research
Research overview
Historical use
Boswellia serrata resin (Shallaki / Salai guggul) has been central to Ayurvedic medicine for over 3,000 years, used primarily for inflammatory joint diseases, respiratory conditions, and gastrointestinal disorders. The Charaka Samhita and Sushruta Samhita document its application for arthritis, diarrhoea, and skin diseases. Frankincense oleoresin has been burned as incense in ancient Egyptian, Jewish, and early Christian traditions, and used topically for wound healing across Mediterranean and South Asian cultures.
Modern research context
Boswellia serrata extracts standardised to boswellic acids (particularly AKBA) are clinically established for inflammatory conditions. The strongest clinical evidence is in osteoarthritis and chronic pain: a 2025 randomised, double-blind, placebo-controlled multicenter trial (Vaidya N et al.) confirmed significant efficacy in knee OA with favourable safety [6]; a 2025 observational cohort (n=103) demonstrated analgesic benefit as add-on therapy for chronic low back pain [4]. A 2025 RCT demonstrated cognitive improvement with a Boswellia-Terminalia chebula combination over 120 days [3]. Bioavailability is a central clinical challenge: a 2024 crossover pharmacokinetic trial in 20 healthy volunteers (Schmiech M et al.) showed micellar formulations achieve 1,720–4,291% higher boswellic acid bioavailability versus native dry extract, with comparable anti-inflammatory pharmacodynamics [2]. Pilot integrative oncology data suggest a survival benefit when Boswellia is combined with other phytochemicals in glioblastoma patients [8].
Adverse effects
Generally well-tolerated in clinical trials up to 12 months. Most common adverse effects: GI symptoms (nausea, diarrhoea, acid reflux) in 5–10% of participants. Rare skin reactions (pruritus, rash) in 1–3%. No significant haematological or hepatic toxicity at standard doses [4, 6].
Contraindications
No absolute contraindications established at recommended doses. Theoretical antiplatelet activity warrants caution with anticoagulants. Avoid in known hypersensitivity to Burseraceae family members. Insufficient safety data for use in pregnancy and lactation.
Clinical and phytochemical data
Used part
Oleoresin gum (standardised extract)
Primary active compounds
3-O-Acetyl-11-keto-β-boswellic acid (AKBA)
11-Keto-β-boswellic acid (KBA)
α-Boswellic acid
β-Boswellic acid
Incensole acetate (diterpene)
Lupeolic acid
Mechanism of action
Highly selective inhibition of 5-lipoxygenase (5-LOX) by AKBA blocks leukotriene B4 (LTB4) and 5-HETE synthesis; this 5-LOX selectivity distinguishes Boswellia from COX-inhibiting NSAIDs and accounts for its favourable gastric tolerability profile [1]. Concurrent suppression of NF-κB transcription factor reduces downstream expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and matrix metalloproteinases [1, 4]. Modest COX-2 inhibition occurs at higher concentrations. AKBA additionally promotes ROS-mediated intracellular clearance of periodontal pathogens in gingival epithelial cells, demonstrating antimicrobial activity. Incensole acetate exerts neuroprotective effects via TRPV3 channel modulation and PPAR-γ agonism [3].
Pharmacokinetics
Absorption
Human pharmacokinetic data are available for Boswellia serrata. A 2024 crossover PK/PD trial in 20 healthy volunteers (Schmiech M et al.) compared single-dose native Boswellia serrata dry extract with a micellar (LipiSperse®) formulation [2]. Native extract showed poor oral bioavailability for all major boswellic acids (KBA, AKBA, α-BA, β-BA) due to high lipophilicity and low aqueous solubility. The micellar formulation achieved relative bioavailability increases of 1,720% to 4,291% for individual boswellic acids versus native extract, establishing formulation-dependent absorption as the primary pharmacokinetic variable [2]. A 2025 RCT of enhanced full-spectrum Boswellia extract confirmed superior bioavailability of optimised preparations in a clinical setting [5].
Distribution
High lipophilicity results in preferential distribution to fatty tissues, liver, and articular cartilage in animal models [1]. AKBA accumulates in inflamed joint tissue, consistent with its clinical efficacy in osteoarthritis. Plasma protein binding is high (>95%) for all major boswellic acids.
Metabolism
Primarily hepatic; boswellic acids undergo glucuronidation and sulfation (phase II conjugation) as principal metabolic pathways. Limited CYP450-mediated oxidative metabolism reported for AKBA at clinical concentrations [1]. Gut microbial hydrolysis of ester bonds generates deacetylated metabolites (11-keto-β-boswellic acid from AKBA). No significant CYP450 auto-inhibition or induction has been reported at standard clinical doses.
Excretion
Biliary excretion of phase II conjugates is the predominant elimination route. Renal excretion of water-soluble glucuronide/sulfate conjugates accounts for a minor fraction. Elimination half-life of AKBA is approximately 4–6 hours following administration of enhanced bioavailability formulations in human volunteers [2].
Safety and interactions
Drug interactions
Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.
Toxicity
Oral acute toxicity is low; LD50 for Boswellia extracts >2 g/kg in rodents. Across multiple RCTs and observational studies spanning OA, chronic back pain, cognition, and integrative oncology, Boswellia has been consistently well-tolerated without clinically significant liver enzyme elevations, haematological changes, or serious adverse events [3, 4, 6, 8].
Special precautions
Pregnancy
Insufficient human safety data. Traditionally avoided during pregnancy. Medicinal-dose preparations not recommended.
Lactation
No human data on excretion in breast milk. Avoid medicinal-dose supplements during lactation.
Hepatic impairment
No specific data. Hepatic glucuronidation is the primary metabolic pathway; dose reduction and monitoring may be appropriate in severe hepatic impairment.
Renal impairment
No specific data. Predominantly biliary elimination suggests renal dose adjustment is likely not required at standard doses.
Sources and references
- [1] - Peng C, Yang Y, Wang Y et al., "From bench to bedside, boswellic acids in anti-inflammatory therapy — mechanistic insights, bioavailability challenges, and optimization approaches.", Frontiers in Pharmacology, 2025, PMID: 41341032
- [2] - Schmiech M, Abdel-Kahaar E, Ulrich J et al., "Single-dose comparative pharmacokinetic/pharmacodynamic study of a micellar formulation versus a native Boswellia serrata dry extract.", Phytomedicine, 2024, PMID: 39033725
- [3] - Salter D, Gupta SVB, Sairam B et al., "A standardized combination of Boswellia serrata and Terminalia chebula extracts to improve cognition in adults with subjective memory complaints.", Frontiers in Nutrition, 2025, PMID: 41438191
- [4] - Giglio M, Mattia C, Sansone P et al., "Efficacy and Safety of Acmella oleracea and Boswellia serrata Extract as Add-On Therapy for Chronic Low Back Pain.", Pharmaceuticals, 2025, PMID: 41471392
- [5] - Mamatha K, Prabhakaran P, Syam Das S et al., "Full-spectrum Boswellia serrata extract with enhanced bioavailability and its co-delivered system with curcumin alleviate moderate spondylitis.", Frontiers in Pharmacology, 2025, PMID: 40667507
- [6] - Vaidya N, Agarwal R, Dipankar DG et al., "Efficacy and Safety of Boswellia serrata and Apium graveolens L. Extract Against Knee Osteoarthritis and Cartilage Degeneration.", Pharmaceutical Research, 2025, PMID: 39875757
- [7] - Mungara AVVP, Shaik NR, M CK, Sureja VP., "CL16019: A Combination of Cissus quadrangularis and Boswellia serrata Extracts Promotes Healing of Distal Radius Fractures.", Journal of Integrative and Complementary Medicine, 2026, PMID: 41896193
- [8] - Bonucci M, Fuggetta MP, Anelli L et al., "New Approach for Enhancing Survival in Glioblastoma Patients: A Longitudinal Pilot Study on Integrative Oncology.", Cancers, 2025, PMID: 40723205